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ABSTRACT
In this study, we demonstrate the identification
of an internal ribosome entry site (IRES) within the
50-untranslated region (50-UTR) of the mouse
mammary tumor virus (MMTV). The 50-UTR of the
full-length mRNA derived from the infectious,
complete MMTV genome was cloned into a dual
luciferase reporter construct containing an
upstream Renilla luciferase gene (RLuc) and a
downstream firefly luciferase gene (FLuc). In rabbit
reticulocyte lysate, the MMTV 50-UTR was capable
of driving translation of the second cistron. In vitro
translational activity from the MMTV 50-UTR was
resistant to the addition of m
7GpppG cap-analog
and cleavage of eIF4G by foot-and-mouth disease
virus (FMDV) L-protease. IRES activity was also
demonstrated in the Xenopus laevis oocyte by
micro-injection of capped and polyadenylated
bicistronic RNAs harboring the MMTV-50-UTR.
Finally, transfection assays showed that the
MMTV-IRES exhibits cell type-dependent transla-
tional activity, suggesting a requirement for as yet
unidentified cellular factors for its optimal function.
INTRODUCTION
Mouse mammary tumor virus (MMTV), the prototype
of betaretrovirus, causes breast cancer in mice (1).
MMTV is transmitted as an exogenous virus through
the milk of infected female mice to newborn pups or
through endogenous proviruses (Mtvs) integrated within
the germline (2). Interestingly, MMTV can infect, replicate
and spread in human cells (3,4), while various MMTV-like
sequences have been identiﬁed in human breast cancers
(5–7) and in liver in a wide range of hepatic disorders
(8). These ﬁndings highlight a possible role for MMTV,
or MMTV-like viruses in human disease. Strikingly, and
although MMTV was discovered more than half a century
ago (9), the biology of this virus remains poorly under-
stood. In this study, we contribute to the understanding of
MMTV by presenting evidence to demonstrate that, akin
to other retroviruses, the MMTV full-length mRNA
harbors an internal ribosome entry site (IRES).
Translation initiation of the vast majority of eukaryotic
mRNAs occurs by a cap-dependent mechanism. This
mechanism involves the recognition of the 50-cap structure
(m
7GpppN) by eukaryotic translation initiation factors
(eIFs), followed by binding of the 40S ribosomal subunit
and scanning downstream to the initiation codon
[reviewed in (10)]. A number of eIFs participate in both
mRNA binding and scanning by the small ribosomal
subunit of the 50-untranslated region (50-UTR). The cap-
binding protein eIF4E together with the ATP-dependent
RNA helicase eIF4A and translation IF eIF4G form the
protein complex eIF4F, which binds and mediates
recruitment of the 40S ribosomal subunit to the 50-cap
structure. 1988 heralded the discovery that translation
of the uncapped picornaviral mRNA is mediated by an
RNA structure, the IRES, which allows assembly of the
translational machinery at a position close to or directly
at the initiation codon (11,12). Since the initial character-
ization of IRES elements in Picornaviridae, viruses
from other families including several members of the
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an IRES (13). An interesting feature, common to
many retroviruses found to harbor an IRES, is that their
viral-encoded proteases cleave eIF4G, hydrolysis that
leads to the inhibition of cap-dependent but not IRES-
mediated translation (14–17). Interestingly, the MMTV
protease eIF4GI both in intact cells and in cell-free
systems, inhibiting cap-dependent translation initiation
(14). Intrigued by these ﬁndings, we set out in this study
to evaluate if the 50-UTR of the MMTV mRNA was
capable of initiating translation using a cap-independent
mechanism. Results presented herein describe an IRES
element present within the 50-UTR of MMTV.
MATERIALS AND METHODS
Cell culture
NIH3T3 (CRL-1658
TM), HeLa (CCL-2
TM), 293T
(CRL-11268
TM) and NMuMG (CRL-1636
TM) cell lines
were grown in Dulbecco modiﬁed Eagle medium
(DMEM, Gibco BRL, Life Technologies Corporation,
Carlsbad, CA, USA) containing 10% bovine fetal serum
(HyClone, Logan, UT, USA) and 1% of penicillin–strep-
tomycin (Gibco BRL). T47D (HTB-133
TM) cells were
grown in RPMI medium without phenol red (HyClone)
containing 10% bovine fetal serum, 1% of penicillin–
streptomycin (Gibco BRL) and 2 mg/ml insulin (Novo
Nordisk A/S, Bagsvaerd, Denmark). All cell lines were
grown at 37 C in a 5% CO2 atmosphere.
Plasmid constructions
For the generation of the bicistronic vector dl 50-UTR-
MMTV, the 50-UTR of MMTV (320bp) was recovered
by PCR from plasmid pGR102 (kindly provided by W.
H. Gu ¨ nzburg and B. Salmons, Institute of Virology,
University of Veterinary Sciences, Vienna, Austria) using
primers MMTV50 (50-CCCGGAATTCGCAACAGTCCT
AACATTCACC-30) and MMTV30 (50-ACCCCCATGGT
CCAATGGCTCACCGTAAC-30). Plasmid pGR102
harbors a biologically active MMTV genomic clone and
has been previously described (18). The MMTV30 primer
was designed to eliminate an additional AUG sequence
found upstream from the original Gag AUG present
only in the pGR102 plasmid and not in wild-type virus
(genbank accession: M15122). Two cysteine residues
were added to the original sequence to allow in-frame
cloning into the dual luciferase vector by creating a
NcoI restriction site as previously described (19).
Nucleotide modiﬁcations with respect to the pGR102
sequence introduced during PCR are indicated above in
bold italics within the sequence of the primer MMTV30.
The amplicon was digested with EcoRI and NcoI (both
restriction sites added by PCR) and inserted into the
intercistronic region of dl HIV-1 IRES plasmid (19)
previously digested with the same enzymes (Fermentas,
Vilnius, Lithuania). The ﬁnal vector, dl 50-UTR-MMTV,
was veriﬁed by sequence analysis (Macrogen Corp,
Rockville, MD, USA). The dl EMCV, dl HIV-1 IRES
and dl HCV IRES plasmids were previously described
(19–21). To generate plasmids without the SV40
mammalian promoter, the dl 50-UTR-MMTV and dl
EMCV vectors were digested with HindIII and MluI
followed by a ligation using T4 DNA Ligase (Fermentas).
In vitro transcription
Uncapped mRNAs were synthesized with T7 RNA
polymerase. In brief, plasmids linearized with the requisite
enzyme were used for in vitro transcription in a 25-ml ﬁnal
volume (Ribomax T7, Promega Corporation, Madison,
WI, USA). Template DNA was digested with DNase I,
and RNA was precipitated with 2.5 M LiCl. RNA was
resuspended in diethyl pyrocarbonate (DEPC)-treated
water. Capped mRNAs were synthesized using the
mMESSAGE mMACHINE High Yield Capped RNA
Transcription Kit (Applied Biosystems/Ambion, Austin,
TX, USA) following manufacturer’s speciﬁcations. The
poly(A) tailing kit (Applied Biosystems/Ambion) was
used to add poly(A) tail to the capped mRNAs according
to the manufacturer’s speciﬁcations. RNA concentrations
were determined spectrophotometrically (NanoDrop
Technology, Wilmington, DE, USA) and RNA integ-
rity was monitored by electrophoresis on denaturing
agarose gels.
In vitro translation
In vitro translations were carried out in nuclease-treated
Rabbit Reticulocyte Lysate or the Flexi rabbit reticulo-
cyte system (RRL, Promega), at 35% (v/v), supplemented
with 20mM amino acids (Promega), 8U/ml Ribolock
Rnase inhibitor (Fermentas), potassium acetate (KOAc)
(in the range of 40–200mM as indicated in the ﬁgure
legend or text), magnesium acetate (MgOAc2) (in the
range of 0.25–1.5mM as indicated in the ﬁgure legend)
and RNA at ﬁnal concentration of 1–6.25ng/ml. For
cap-analog experiments, Flexi Rabbit Reticulocyte
System was pre-incubated for 15min at 30 C with 250
or 500mM of the Ribo-m7G-Cap Analog (Promega),
then bicistronic mRNAs (6.25ng/ml) were added for in
vitro translation. Reactions were conducted in 80mM
KOAc and Mg
2+ were adjusted for each experimental
condition by addition of MgOAc2. Reactions that lacked
cap analog were conducted in a ﬁnal concentration of
0.75mM Mg
2+, reactions with 0.25mM of m
7GpppG
were conducted in a ﬁnal concentration of 1.125mM
Mg
2+ and those with 0.5mM of m
7GpppG were con-
ducted in a ﬁnal concentration of 1.5mM Mg
2+,a s
suggested by others (22). For the foot-and-mouth
disease virus (FMDV) L-protease assays, uncapped
RNA of the FMDV L-protease was in vitro translated in
nuclease-treated RRL as described above from the pLb
plasmid (a kind gift of Dr G. Belsham, Institute
for Animal Health, Pirbright, UK) (23). In brief, 220ng/
ml of the FMDV L-protease uncapped RNA was
translated in 35% (v/v) of RRL for 90min. The
L-protease-RRL was diluted in fresh RRL 35% (v/v) in
a ratio of 1:2 and 1:4. The diluted L-protease-RRL was
added to the fresh RRL used for the translation of the
bicistronic mRNAs to a ﬁnal concentration of 2 and 4%
(v/v) of Protease L. Translation reactions were incubated
at 30 C for 90min. Fireﬂy luciferase (FLuc) and Renilla
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DLR
TM Assay System (Promega) according to manufac-
turer’s instructions on a Sirius Single Tube Luminometer
(Berthold Detection Systems GmbH, Pforzheim,
Germany).
Western blot
eIF4GI cleavage by FMDV L-protease was assessed by
5–20% gradient SDS–PAGE of RRL (10ml), followed
by transfer to nitrocellulose (Pierce Biotechnology, Inc.
Rockford, IL, USA), and eIF4GI detection using a
mixture of well-characterized polyclonal antibodies
against the N- and C-terminal fragments of eIF4GI
(kindly provided by Dr L. Carrasco, Centro de Biologı´a
Molecular Severo Ochoa, Madrid, Spain), as previously
described (24,25).
DNA transfection
Cells were seeded at 1 10
5cell/well in 12-well culture
plates. DNA transfection was performed at 60%
conﬂuency by the JetPei system (Polyplus-transfection
SA, Illkirch, France) according to manufacturer’s
protocols. After 24h, the culture medium was removed
and the cells were directly mixed with the Passive Lysis
buﬀer supplied with the DLR
TM Assay System (Promega).
FLuc and RLuc activities were measured as described
above. The activity of b-galactosidase was measured
in the same cells using the Beta-Glo
TM Assay System
according to manufacturer’s protocols (Promega).
Protein concentration was determined by a Bradford
assay using the Bio-Rad Protein Assay (Bio-Rad
Laboratories, Inc., Hercules, CA, USA).
RNA, DNA extraction, PCR and RT-PCR
Cells in culture were trypsinized (Gibco BRL) and
resuspended in DMEM (Gibco BRL) containing 10%
bovine fetal serum (HyClone). Cells were collected
by centrifugation at 710g for 5min and washed three
times in phosphate-buﬀered saline (PBS, 137mM NaCl,
2.7mM KCl, 4.3mM Na2HPO4 7H2O, 1.4mM KH2PO4,
pH 7.4) at 4 C. For RNA extraction, the cell pellets were
directly lysed in solution D (4M guanidine thiocyanate,
25mM sodium citrate pH 7.0, 0.55% w/v sarkosyl, 0.1M
b-mercaptoethanol) at 500ml/10
5 cells, and 1/10 volume of
sodium acetate 3M pH 4.2, 1 volume of water-saturated
phenol and 1/10 volume of chloroform/isoamyl alcohol
(24:1) were added, vortexed for 15s and incubated
15min on ice. The mixture was centrifuged for 15min at
16000g at 4 C, the aqueous phase was transferred to a
new tube, precipitated with 500ml of isopropanol at
 20 C for 3h and centrifuged for 30min at 16 000g at
4 C. The pellet was washed with 100ml of 75% ethanol,
centrifuged for 5 min at 16000g at 4 C and resuspended
in 20ml of DEPC–water and was DNase-treated and
re-extracted as described above. RNA integrity was
monitored by electrophoresis on denaturing agarose
gels and quantiﬁed by spectrophotometry (NanoDrop
Technology). DNA was extracted from cells using the
EZNA
TM kit (Omega Bio-Tek, Inc., GA, USA) accord-
ing to the manufacture manual. DNA concentration
was determined by spectrophotometry (NanoDrop
Technology).
The RT-PCR assay was carried out using the
SuperScript
TM III One-Step RT-PCR System with
Platinum Taq DNA polymerase kit (Invitrogen, Life
Technologies Corporation, Carlsbad, CA, USA) accord-
ing to manufacturer’s protocol, using 3mg of total RNA
and primers p2anti (50-TCTCTTCATAGCCTTATGCA
GTTG-30) and Pforluc (50-CATGACTTCGAAAGTTTA
TGATC-30). The PCR assay was conducted using primers
p2anti and Pforluc, 100ng of total DNA and the Go Taq
Green Master mix (Promega), according to the manufac-
turer’s protocol.
Oocyte harvesting and RNA microinjection
Oocytes were isolated from Xenopus laevis ovarian
fragments by manual dissection as previously described
(26). Oocytes were incubated at 15 C for 24h in
standard Barth’s solution supplemented with 10 IU/l pen-
icillin–streptomycin and 2mM pyruvate (26). To evaluate
viral IRES activity in oocytes, 6.25ng of in vitro
transcribed capped and polyadenylated RNA was
microinjected into each oocyte with glass micropipettes
calibrated to deliver a ﬁnal volume of 50nl (27,28).
After 3, 6, 12 or 24h (refer to the ﬁgure legend) oocytes
were lysated in Passive Lysis buﬀer (Promega), and
centrifuged at 16000g for 5min, and 1–5ml of the
supernatant was used in the detection assay using the kit
DLR
TM Assay System (Promega).
HIV-1 Rev and MMTV Rem plasmid constructs for
protein expression
The HIV-1 rev gene was derived from the plasmid
pCMVsrevBF and inserted into the commercially avail-
able prokaryotic expression vector pET-3a (Stratagene,
La Jolla, CA, USA) to create the intermediate plasmid
pETsRev and thereafter pETsRevCHis, wherein six
histidine residues (His) were fused in-frame immediately
downstream of rev to generate a C-terminal His tag. These
plasmids have been previously described (29).
The MMTV rem gene used in these studies has
been previously described in detail (30) and was
obtained as a kind gift from Dr S. Indik (Institute for
Virology, University of Veterinary Medicine Vienna,
Austria). To insert the rem gene into the pET-3a vector
for prokarytotic protein expression, the rev gene in the
vector pETsRev was removed by restriction digestion
with NdeI and BamHI and replaced by an NdeI/BamHI
rem PCR fragment to create the intermediate cloning
plasmid pETRem. Using a PCR mutagenesis method
that has been previously described (31), a C-terminal His
tag was then inserted immediately downstream of rem by
means of overlapping, matching, sense and anti-sense
ends. Brieﬂy, by annealing the two products together
in a reaction without primers, the His tag became
inserted in-frame immediately upstream of the rem stop
codon. In a third PCR step, using only outside primers,
a complete RemCHis fragment was then ampliﬁed and
could be re-inserted into pETRem vector using again
the NdeI and BamHI sites. The resulting plasmid was
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for protein expression of the active, signal peptide
(SP) region component of the full-length rem protein
(RemSP). RemSP is the nucleocytoplasmic shuttling
RNA transport factor component of Rem (30,32). Long-
template PCR (Expand Kit from Roche Molecular
Systems, Inc., Branchburg, NJ, USA) was performed to
remove the C-terminal region of Rem, leaving only the SP
region and the product was ligated to reform the fusion
with the C-terminal His tag. The resulting plasmid
pETRemSPCHis was sequenced to conﬁrm the correct,
tagged RemSP sequence.
Production of recombinant Rev and Rem protein
pETsRevCHis and pETsRemCHis were transformed by
heat shock into BL21(DE3) bacteria (Stratagene)
according to the manufacturer’s instructions. To ensure
optimal activity, purity and quantity, Rev was obtained
under denaturing and refolding conditions as previously
described in detail (29). In contrast to Rev, the majority of
RemSP protein was expressed as a soluble protein after 3h
at 37 C with 1mM isopropyl-b-D-thio-galactopyranoside
stimulation. Stimulated bacterial pellet was resuspended in
PR buﬀer (20mM phosphate buﬀer pH 7.4, 0.5M NaCl,
20mM Na-EDTA) and spiked with protein inhibitor
complex for His-tagged proteins (Sigma Aldrich, St
Louis, MO, USA) as per manufacturer’s instructions.
Lysozyme (Sigma), dissolved in 10mM phosphate buﬀer
with 0.5M NaCl, was added to a ﬁnal concentration of
2mg/ml and the sample was subjected to two sonication
and vortexing cycles on ice to disrupt bacteria. To destroy
nucleic acids, 500U Benzonase (Sigma) were added per
gram of pellet in the presence of a ﬁnal concentration of
20mM MgCl2. The sample was centrifuged at high speed
to remove remaining debris and the supernatant used for
protein puriﬁcation using HisTrap FF Crude (fast ﬂow)
chelating high-performance (HP) sepharose columns (GE
Healthcare, Piscataway, NJ, USA) and the native protein,
step elution programme of the A ¨ KTAprime protein puri-
ﬁcation unit (GE Healthcare) according to the manufac-
turer’s guidelines. To localize RemSP protein in eluted
fractions, aliquots of the fractions were analyzed by
SDS-PAGE followed by silver staining and the positive
fractions containing only pure protein were concentrated
via ultraﬁltration using a regenerated cellulose membrane
with a molecular weight cut-oﬀ of 5000 D Centricon units
(Millipore, Billerica, MA, USA). Protein concentration,
typically  5mg/ml, was determined by the Bradford
assay (Bio-Rad Laboratories). An aliquot of the ﬁnal
refolded, puriﬁed and concentrated RemSP protein was
tested by western blot to conﬁrm correct identity of the
protein. Western blot was performed using either an anti-
p14 (RemSP) antisera (a kind gift from Dr J. Hochman,
the Hebrew University of Jerusalem, Jerusalem, Israel) or
a commercially available anti-His-tag antisera. Coomassie
staining also showed the protein to be of high integrity
and >99% purity. RemSP aliquots were frozen at
 80 C in 15% glycerol. Activity was assayed by electro-
mobility gel-shift assay (EMSA).
EMSA
For the production of radio-labeled test RNAs (RRE),
10% of the total CTP in an in vitro transcription
reaction (RiboMax T7, Promega) was substituted for
[a-
32P]CTP (GE Healthcare). RNA-protein binding
reactions were carried out in DEPC-treated PBS contain-
ing 50mg/ml BSA, 10mg of eukaryotic tRNA and 10 U of
RNaseOut (Invitrogen). First, 1–2mg of Rev or RemSP
was added to the reaction mix and left to equilibrate for
15min at room temperature before
32P-labeled RNA
probe was added and incubated for a further 15 min.
Samples were then subjected to 5% 60:1 native TBE
PAGE. For competition experiments, unlabeled RNA
was DNase treated, puriﬁed via phenol/chloroform
extraction and tested for integrity by agarose gel
electrophoresis.
RESULTS
The MMTV 50-UTR drives translation when in the
context of a bicistronic mRNA
The full-length mRNA of some retroviruses can initiate
protein synthesis through both a cap-dependent and cap-
independent mechanism (13,33). With the exception of
HIV-2 (34), IRES activity in retroviruses is mainly
found within the 50-UTR. In HIV-1 and SIV, a second
IRES is found within the Gag-coding region (19,35–37).
At present, an IRES element is deﬁned solely by func-
tional criteria and cannot yet be predicted by the
presence of characteristic RNA sequences or structural
motifs (38). Thus, to evaluate the possibility of an IRES
element within MMTV, the 50-UTR of its full-length
mRNA was cloned into a dual luciferase (dl) reporter con-
struct containing an upstream Renilla luciferase gene
(RLuc) and a downstream ﬁreﬂy luciferase gene (FLuc).
The 50-UTR of MMTV was recovered from the pGR102
plasmid (18), which harbors the infectious, complete
MMTV genome, as indicated in the ‘Material and
Methods’ section. To ensure that the two cistrons
are independently translated, a defective encephalo-
myocarditis virus IRES (EMCV), known to inhibit
ribosome reinitiation and readthrough (19,21), was
inserted upstream of the MMTV 50-UTR (Figure 1). In
this context, the translational activity of the MMTV
50-UTR was monitored using FLuc activity as the
readout, while the RLuc reporter gene serves as an
upstream translational control. In vitro, IRES-mediated
translation initiation is highly dependent on the concen-
tration of potassium and magnesium present within the
translation mixture (19,35). Thus, in the ﬁrst series of
experiments, the putative IRES activity of the MMTV
50-UTR was assessed by programming the nuclease-
treated rabbit RRL with 1ng/ml of RNA for translation
in the presence of a range of KOAc or MgOAc2 concen-
trations (Figure 2A). RLuc and FLuc activities obtained
in RRL (40mM KOAc and 0.25mM MgOAc2) without
additional salt supplementation were arbitrarily set to
1 (±SEM). The data demonstrate that, when in the
context of a bicistronic mRNA translation driven by the
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RRL programmed with 1ng/ml of RNA at 60mM
KOAc (Figure 2A, compare dl 50UTR-MMTV and
dlEMCV). Interestingly, and in keeping with what has
been described for other retroviral IRESes (19,35), both
cistrons showed a distinct response to varying K
+ and
Mg
2+ concentrations, which itself is symptomatic of
independent translation for RLuc and FLuc cistrons.
Therefore, the MMTV 50-UTR emerges as a good candi-
date for harboring an IRES element.
The MMTV 50-UTR directs translation in RRL
when cap-dependent translation initiation is inhibited
We then evaluated the translational activity of the MMTV
50-UTR in salt-optimized RRL when cap-dependent
translation initiation was inhibited, beginning with the
addition of m
7GpppG cap-analog to the in vitro trans-
lation reaction. The rational behind this approach lies
in the competitive binding by cap-analog of the transla-
tion IF eIF4E, the cap-binding protein of the translation
initiation complex (39). We used previously characterized
bicisctronic mRNAs harboring IRES elements from either
HIV-1 or HCV as experimental controls (Figure 1)
(19,20). In these experiments, the dl EMCV vector, con-
taining only the defective encephalomyocarditis virus
IRES inserted upstream of the FLuc reporter (Figure 1),
was used as a negative control (19,20). The relative RLuc
and FLuc activities for each RNA in the absence of
cap-analog were arbitrarily set to 100% (±SEM). RLuc
and FLuc values for the dl EMCV dl RNA were
compared against the dl 50UTR-MMTV RNA (Figure
2B). m
7GpppG cap-analog negatively impacted on the
translation of RLuc, the ﬁrst cistron, in all bicistronic
RNAs, while it did not aﬀect synthesis of FLuc driven
by the MMTV 50-UTR, the HIV-1 IRES or the HCV
IRES (Figure 2B). These experiments were conducted in
optimal salt conditions (Figure 1). Considering chelation
of Mg
2+ ion by m
7GpppG cap-analog (22), ion concen-
tration was adjusted accordingly as indicated in ‘Materials
and Methods’ section. Interestingly, inhibition of
cap-dependent translation by the addition of cap-analog
initially increases translation driven from the MMTV
50-UTR (Figure 2B), observations which endorse
previous reports describing a stimulation of IRES-
dependent translation when cap-dependent translation is
inhibited in vitro (19,35,40). Intriguingly, at high
concentrations of cap-analog (500mM) activity from the
HIV-1 IRES was not increased (Figure 2B). Even though
these observations cannot be readily explained, they are
consistent with what has been previously described for the
HIV-1 IRES under conditions known to inhibit cap-
dependent translation initiation [see Figure 5 of (19)].
Next we examined the impact of eIF4GI cleavage on the
translation of dl-mRNAs harboring the 50-UTR MMTV
or the HCV IRES. The L-protease from FMDV cleaves
eIF4GI into an N-terminal (one-third of the molecule) and
a C-terminal (two-thirds of the molecule) domain (41).
This proteolytic cleavage of eIF4GI resulted in inhibition
of cap-dependent translation, while IRES-driven transla-
tion was unaﬀected or sometimes even stimulated (42,43).
FMDV L-protease was prepared in RRL as previously
described (44), and 2 or 4% v/v of RRL-L protease was
added to fresh RRL as indicated in the ‘Materials and
Methods’ section. Dual luciferase mRNAs were translated
Figure 1. Schematic representation of the bicistronic mRNAs used in this study. Bicistronic mRNAs dl EMCV (19,21), dl HIV-1 IRES (19) and dl
HCV IRES (20) have been previously described. RNAs correspond to the dual luciferase (dl) reporter construct containing an upstream Renilla
luciferase gene (RLuc) and a downstream ﬁreﬂy luciferase gene (FLuc). In these RNAs, EMCV corresponds to a defective encephalomyocarditis
virus internal ribosome entry site known to inhibit ribosome re-initiation and readthrough (19,21), while HIV-1 IRES and HCV IRES correspond to
the IRESes described in the HIV-1 50-UTR (19) and the HCV 50-UTR (20).
622 Nucleic Acids Research, 2010,Vol. 38,No. 2Figure 2. Assessment of IRES activity within the MMTV-50-UTR in nuclease-treated rabbit RRL. (A)d l5 0-UTR MMTV and dl EMCV in vitro
transcripts with 50-caps were synthesized using T7 RNA polymerase and translated in RRL in the presence of diﬀerent concentrations of KOAc and
MgOAc2.( B) In vitro transcribed capped bicistronic RNA corresponding to dl EMCV (19,21), dl 50UTR-MMTV, dl HCV IRES (20) or dl HIV-1
IRES (19) were translated in salt-optimized RRL in the absence ( ) or presence of 250 or 500mMo fm
7GpppG cap-analog. In these assays, Mg
2+
ions were adjusted to optimal concentrations as indicated in ‘Materials and Methods’ section (22). RLuc and FLuc luciferase activities [relative light
units (RLUs)] were measured as indicated in ‘Materials and Methods’ section. The relative RLuc and FLuc activities for each RNA in the absence of
cap-analog were arbitrarily set to 100% (±SEM). RLuc and FLuc values for the dl EMCV RNA were compared against the dl 50UTR-MMTV
RNA. Values are the mean±SEM from three independent experiments each conducted in triplicates. (C) Analysis of eIF4GI cleavage. RRL
translation reactions (10ml) with (lane 2) or without (lane 1) FMDV L protease (2% v/v) were resolved by SDS gradient 5–20% PAGE, transferred
to nitrocellulose paper and incubated with a mixture of polyclonal antibodies against the N- and C-terminal fragments of eIF4GI as described in
‘Materials and Methods’ section. Positions of molecular mass standards (in kilo daltons) are shown. Polyclonal antibodies against N- and C-terminal
peptides of eIF4GI were described previously (24). The cleavage products, CP in the ﬁgure, obtained with the FMDV-L protease treatment have been
previously characterized (41). (D) Capped bicistronic RNA dl 50UTR-MMTV or dl HCV IRES (20) were translated in RRL in the absence ( )o r
presence of 2 or 4% v/v of FMDV-L protease. The relative RLuc and FLuc activities for each RNA in the absence of FMDV-L protease were
arbitrarily set to 100% (±SEM). Values are the mean±SEM from three independent experiments each conducted in triplicates.
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eIF4GI was monitored (2% v/v of RRL-L protease;
Figure 2C) by immunoblotting as previously described
(24,25). The relative RLuc and FLuc activities for each
RNA in the absence of L-protease were arbitrarily set to
100% (±SEM). Our results show that the cleavage of
eIF4GI (Figure 2C) negatively impacts on translation of
RLuc, the ﬁrst cistron, from the dl 50UTR-MMTV RNA,
without aﬀecting the synthesis of FLuc (Figure 2D).
Similar behavior was observed with the dl HCV IRES
mRNA (Figure 2D). Together, these data strongly
suggest that the 50-UTR of the MMTV full-length
mRNA harbors an IRES.
The MMTV 50-UTR mediates cap-independent
translation initiation in X. laevis oocytes
To further challenge our ﬁndings, we next evaluated if
the 50-UTR of MMTV could drive cap-independent trans-
lation in X. laevis oocytes, an experimental system which
has been proven useful for the study of viral IRESes
(45,46). Diﬀerent concentrations of in vitro synthesized
capped and polyadenylated RNA corresponding to
dlEMCV, dl HCV IRES and dl 50UTR-MMTV
vectors were microinjected into the cytoplasm of
X. laevis oocytes. RLuc and FLuc activities were measured
24h post-injection (Figure 3A). RNA concentrations of
 12.5ng gave rise to saturating RLuc activity 24h after
injection. Thus, experiments were repeated using 6.25ng
of each RNA and RLuc and FLuc activities were now
measured at diﬀerent times post-injection (Figure 3B).
The RLuc levels from the dl HCV IRES and the dl
50UTR-MMTV mRNAs were comparable at all time
points (Figure 3B), suggesting not only that cap-
dependent translation initiation is functional in oocytes,
but also conﬁrming that similar amounts of RNA were
microinjected in all experiments. A low level of expression
from the second cistron of the dlEMCV reporter RNA,
considered to be background, was also observed (Figure
3). Notably, FLuc was expressed above the dlEMCV
background levels, from the dl 50UTR-MMTV RNA
(Figure 3), demonstrating that the MMTV 50-UTR is
capable of driving cap-independent translation in
X. laevis oocytes. As an additional control dl EMCV,
dl HCV IRES and dl 50UTR-MMTV DNA plasmids were
microinjected into the cytoplasm of X. laevis oocytes, in all
cases the RLuc and FLuc activity could not be detected
(data not shown) discarding the possibility of de novo
RNA synthesis, cryptic promoter activity and RNA
splicing starting from a DNA template. Together, these
data provide substantial evidence supporting the
presence of an IRES within the MMTV 50-UTR.
Furthermore, these data also suggest that additional
viral proteins are not required for MMTV-IRES activity
in X. laevis oocytes.
MMTV 50-UTR-mediated internal initiation exhibits
cell type-dependent translational activity
The precise molecular mechanism by which the host
translational apparatus recognizes retroviral IRESes
is unknown (13). However, the study of picornaviral
IRESes has revealed that cap-independent translation ini-
tiation uses both canonical eIFs, as well as speciﬁc cellular
proteins known as IRES trans-acting factors (ITAFs) (47).
The presence or absence of particular ITAFs alters IRES
activity in diﬀerent cellular backgrounds (48,49). Thus,
having established the presence of an IRES within the
50-UTR of the MMTV RNA and knowing that IRES
eﬃciencies depend on the cellular background, we next
evaluated MMTV IRES activity in a range of cell types.
Cells used in these experiments included NMuMG
(normal murine mammary gland), HeLa (human cervical
cancer cells), 293-T (human embryonic kidney cells),
T47D (human breast carcinoma) and NIH 3T3 (mouse
embryonic ﬁbroblast). Cells were co-transfected with
either dl EMCV or dl 50UTR-MMTV and pcDNA3.1
lacZ plasmids. The expression from both cistrons was
assessed and normalized against the transfection control
b-galactosidase. The normalized relative translation
eﬃciency (RTE) [(FLuc/RLuc)/(total protein) (b-
galactosidase)] ratio, depicted in the ﬁgures as (FLuc/
RLuc) was used as an index of MMTV IRES activity.
In accordance to what has been described for other
IRESes (48,49), the RTE of MMTV IRES-driven transla-
tion varied widely between cell lines (Figure 4A). The
MMTV IRES showed greatest activity in NMuMG cells
and HeLa cells (Figure 4A). These observations suggest
that for optimal activity, the MMTV IRES requires as yet
unidentiﬁed cell factors.
FLuc expression from the dl 50-UTR MMTV plasmid
in NMuMG cells is not due to cryptic promoter
activity within the MMTV 50-UTR
Studies to identify internal initiation in isolated viral
or cellular UTR segments utilizing the transfection of
bicistronic reporter plasmids have been strongly criticized.
It is recognized that a caveat to the above described
approach is false-positive IRES activity attributable
to cryptic promoter activity or splicing of the tested
sequence within cells. Alternative splicing would poten-
tially bypass the ﬁrst cistron, while allowing the expression
of the second cistron from the SV40 promoter. Even
though experiments shown in Figure 3 addressed the pos-
sibility of cryptic promoter activity and of alternative
splicing, data are limited to X. laevis oocytes. Thus, we
veriﬁed the presence of the full-length bicistronic RNA in
transfected cells. To achieve this, total RNA was extracted
from cells and analyzed by RT-PCR as described by
others (34,48,50,51). Results conﬁrmed the presence of
the full-length bicistronic mRNA for both constructs, dl
EMCV and dl 50UTR-MMTV, in all studied cell lines
(Figure 4B).
To exclude the possibility that the FLuc synthesized
from the dl 50UTR-MMTV RNA is associated with
cryptic promoter activity, we removed the SV40
promoter from the bicistronic constructs (Figure 5A).
This approach has been suggested and used by others
for a similar purpose (52). In this setting, expression
of the second transgene implies that the DNA coding
for the IRES possesses cryptic promoter activity.
Promoter-less bicistronic constructs were then transfected
624 Nucleic Acids Research, 2010,Vol. 38,No. 2into NMuMG cells, and 24h later cells were processed as
indicated in the ‘Materials and Methods’ section and
DNA, RNA and protein analyses were conducted. PCR
conﬁrmed that all cells were positively transfected with the
dl plasmids (Figure 5B). RNA analysis conﬁrmed the
expression of the bicistronic (RLuc-FLuc) RNA only in
cells transfected with the constructs that contained an
active SV40 promoter (Figure 5C). Analysis of RLuc
and FLuc activities conﬁrmed that the proteins were not
expressed for the dl 50UTR-MMTV lacking the SV40
promoter (Figure 5D). We thereby exclude the possibility
that expression of FLuc from the dl 50UTR-MMTV
constructs observed in NMuMG cells is due to the
production of an additional transcript encoding FLuc
via a cryptic promoter. Consequently, we conclude that
the 50-UTR of the full-length mRNA of MMTV harbors
an IRES.
In vitro, activity of the MMTV IRES is not modulated
by the MMTV Rem or HIV-1 Rev proteins
MMTV encodes a functional homolog of the HIV-1
nuclear export protein Rev (Rem) (30,53). Rem is a
33-kDa protein that is encoded by a doubly spliced
mRNA. The N-terminal portion of Rem contains
nuclear and nucleolar localization signals as well as an
arginine-rich motif similar to the HIV-1 Rev RNA
export protein (30,53). Rev is a 116 amino acid nuclear–
cytoplasmic shuttling RNA-binding protein absolutely
required for the cytoplasmic accumulation of intron-
containing HIV-1 mRNAs (54). Rev achieves this by
binding in a highly speciﬁc manner to an RNA secondary
structure found in the envelope gene (env) intron called the
Rev responsive element (RRE) (55). Several reports
indicate, however, that the role of Rev is not restricted
to the nuclear export of RRE-containing mRNA (56).
Figure 3. Assessment of IRES activity present within the MMTV-50-UTR in X. laevis oocytes. (A) Diﬀerent concentrations (3.1, 6.25, 12.5 or
25ng) of capped and polyadenylated RNA corresponding to dl EMCV, dl 50UTR-MMTV or dl HCV IRES vectors were microinjected into
X. laevis oocyte as described in ‘Material and Methods’ section. Oocytes were harvested 24h after the microinjection and processed. Renilla luciferase
(RLuc) and Fireﬂy luciferase (FLuc) activities were determined (in RLUs). The RLuc (left panel) and FLuc (right panel) activities for each RNA
in each concentration are shown. Oocytes injected with 12.5 and 25ng of RNA showed saturating RLuc values. RLU values for oocytes injected
with 25ng RNA were obtained by diluting samples (1/4 volumes) prior to measurement. Each value is the mean±SEM from at least nine
oocytes obtained from two diﬀerent animals. (B) Capped and polyadenylated RNA corresponding to the dl EMCV, dl 50UTR-MMTV or
dl HCV IRES vectors (6.25ng) were microinjected into X. laevis oocyte as described in ‘Material and Methods’ section. Oocytes were harvested
3, 6, 12 or 24h after the microinjection and processed. RLuc and FLuc activities were determined (in RLU). The RLuc (left panel) and FLuc (right
panel) activities for each RNA in each concentration are shown. Each value is the mean±SEM from at least three oocytes obtained from diﬀerent
animals.
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localization to polysomes, enhancing their use by the
cellular translational machinery (57–59). Additionally,
Rev has been shown to bind the 50-UTR of HIV-1
mRNA (60), binding that is implicated in a direct modu-
lation of translation initiation of the HIV-1 mRNA (61).
This translational modulation is achieved in a RRE-
independent fashion. Interestingly, Rev is capable of inter-
acting with the MMTV Rem responsive element (RmRE),
while Rem can interact with the HIV-1 RRE, in both
cases increasing expression of transcripts carrying viral
sequences (29,32,62). Based on these ﬁndings, we next
sought to establish if Rem and Rev could modulate
translation from the MMTV IRES in the context of a
bicistronic RNA lacking the MMTV-RmRE or HIV-
RRE sequences. These experiments were conducted in
RRL using in vitro transcribed bicistronic RNA and
recombinant MMTV Rem (RemSP) or HIV-1 Rev
proteins. In order to test the functionality of the
recombinant Rev and RemSP proteins in terms of their
ability to bind RNA, an RNA EMSA was performed
(Figure 6A). Recombinant Rev clearly binds to and
shifts HIV-1 RRE RNA (compare lane 1 with 2). Also,
recombinant RemSP clearly binds to and shifts HIV-1
RRE (compare lane 1 with 7). These observations
conﬁrm that the recombinant proteins conserve their
ability to bind the HIV-1 RRE. With increasing
concentrations of competitor RNA (tRNA), a shift can
still be detected in the case of Rev (lanes 2–6) and
RemSP (lanes 7–11) showing that both interactions are
of high speciﬁcity. Both Rev and RemSP are capable of
binding random RNA sequences, no doubt due to their
Figure 4. A comparison of the eﬃciency of MMTV-IRES-initiated translation in cell lines of diﬀerent origin. (A) NMuMG, 293-T, HeLa, T47D and
NIH 3T3 cells were co-transfected with either dl EMCV (200ng) or dl 50UTR-MMTV (200ng) and pcDNA3.1 lacZ (50ng) plasmids. b-
Galactosidase and total proteins were quantiﬁed as indicated in ‘Materials and Methods’ section. RLuc and FLuc activities were measured and
normalized by the total protein content and the b-galactosidase activity. Thus, the [(FLuc/RLuc)/(total protein) (b-galactosidase)] ratio was used as
an index of IRES activity. The ratio obtained with the dl EMCV and the dl 50UTR-MMTV plasmids are independently depicted. Values are the
mean±SEM from three independent experiments each conducted in triplicates. (B) NMuMG, 293-T, HeLa, T47D and NIH 3T3 cells were co-
transfected with either dl EMCV (200ng) or dl 50UTR-MMTV (200ng) and pcDNA3.1 lacZ (50 ng) plasmids. Total RNA was extracted from each
transfected cell type and quantiﬁed. Extracted RNA (3mg) was used as template in a one-step RT-PCR designed to speciﬁcally detect the dl EMCV
and dl 50UTR-MMTV bicistronic RNA (bottom panel). A schematic representation of the experimental procedure showing the primers and the size
of the expected amplicons is presented (top panel). In vitro transcribed FLuc monocictronic RNA (200ng; lane 2), RLuc monocistronic RNA
(200ng; lane 3) or an equimolar mixture of both the FLuc and RLuc monocistronic RNAs (lane 4) were included as negative controls. An additional
water control ( ) for the RT-PCR was included (lane 5).
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with 16 and 17, respectively); however, this interaction is
disrupted at relatively low concentrations of competitor
RNA (lanes 15 and 19, respectively). Based on the above
evidence, we conclude that the recombinant Rev and
RemSP proteins utilized herein were fully competent
in their ability to interact with RNA.
In the next set of experiments, capped and
polyadenylated RNA generated from the dl 50UTR-
MMTV plasmid was mixed with diﬀerent concentrations
Figure 5. Analysis of a promoter-less bicistronic construct containing the MMTV 50-UTR sequence. (A) Schematic representation of the bicistronic
constructs. The SV40 promoter from dl EMCV (lane 3) or dl 50UTR-MMTV was removed to generate the equivalent promoter-less (SV40)
vectors. (B) NMuMG cells were transfected with DNA (200ng) corresponding to the vectors depicted in (A) together with the pcDNA3.1 lacZ
(50ng) plasmid. Total DNA was extracted from transfected NMuMG cells and the presence of the transfected plasmids was conﬁrmed by PCR.
Plasmids (100ng) dl EMCV (lane 3) or dl 50UTR-MMTV (lane 2) were used as ampliﬁcation controls. (C) Total RNA was extracted from
transfected NMuMG cells and the presence of transcripts for the dl EMCV (lane 3), the dl 50UTR-MMTV, the  SV40-dl EMCV and  SV40-dl
50UTR-MMTV was evaluated by a one-step RT-PCR designed to detect the bicistronic RNA (depicted in Figure 3B). In vitro transcribed RNA
(100ng) generated from plasmids dl EMCV (lane 3) or dl 50UTR-MMTV (lane 2) were used as ampliﬁcation controls. The presence of template
RNA was conﬁrmed in parallel by loading the total RNA (10mg) used in the RT-PCR onto a 0.7% denaturing agarose gel. (D) NMuMG cell were
co-transfected with either the SV40 or  SV40 version of dl EMCV (200ng) or dl 50UTR-MMTV (200ng) plasmids together with the pcDNA3.1
lacZ (50ng) plasmid. Cells were processed, and b-galactosidase and total proteins were quantiﬁed. RLuc and FLuc activities were measured, and data
are presented as [RLuc/(total protein) (b-galactosidase)] (left panel) and [FLuc/(total protein) (b-galactosidase)] (right panel).
Nucleic AcidsResearch, 2010, Vol.38,No. 2 627Figure 6. Neither the MMTV Rem nor the HIV-1 Rev proteins are directly implicated in translation driven from the MMTV-IRES. (A) RNA-
binding activity as a measure of functionality for recombinant Rev and RemSP proteins was determined by radio-labeled RNA EMSA. Recombinant
Rev binds to and shifts HIV-1 RRE RNA (compare lane 1 with 2). Recombinant RemSP binds to and shifts HIV-1 RRE (compare lane 1 with 7).
The speciﬁcity of the interaction of Rev (lanes 2–6) and RemSP (lanes 7–11) with the target RNA was evaluated by adding increasing concentrations
of competitor RNA (tRNA). The use of random RNA sequences as control conﬁrmed that both RemSP and Rev can bind RNA at high protein
concentrations (compare lanes 12 and 13 with 16 and 17, respectively). Binding is lost when relatively low concentrations of competitor RNA are
present (lanes 15 and 19, respectively), i.e. there is no speciﬁcity for binding to the control RNA. The concentration of radio-labeled test RNA in all
test samples was  0.5mM. (B and C) T7 polymerase-generated capped and polyadenylated dl 50UTR-MMTV RNAs were mixed with diﬀerent molar
concentrations of recombinant RemSP (B) or Rev (C) protein. The mean RLuc and FLuc luciferase activities in absence of the recombinant protein
were arbitrarily set at 100% (±SEM). Values are the mean±SEM from three independent experiments each conducted in triplicates. RLuc and
FLuc values are relative to the 100% activity in the absence of recombinant protein (left panel). The (FLuc/RLuc) ratio was used as an index of
IRES activity (right panel).
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were added to the RRL at the indicated molar ratios
(Figure 6B). The mean luciferase activity in the absence
of the recombinant protein was arbitrarily set at 100%
(±SEM). The mean FLuc/RLuc ratio was then used as
an index of IRES activity where the ratio in the absence
of recombinant protein was arbitrarily deﬁned as 1
(Figure 6B). In our hands, this form of recombinant
RemSP did not modulate translation from the MMTV
IRES in RRL, as both cistrons in the bicistronic mRNA
were aﬀected similarly (Figure 6B; right panel). Similar
results were obtained when Rev recombinant protein
was added to the translation mix (Figure 6C; right
panel). Collectively, our data suggest, at least under
these experimental conditions in RRL, that HIV-1 Rev
protein does not exert translational control over the
MMTV-IRES.
DISCUSSION
Much like eukaryotic mRNAs, retroviral mRNAs are
capped at their 50-ends and contain a 30-poly(A) tail.
Interestingly, the presence of IRES elements within the
viral mRNA has been described in a large number of
retroviruses and retrotransposons [reviewed in (13)].
Retroviral IRESes have generally been identiﬁed by
using heterologous bicistronic mRNAs. Nevertheless, the
real requirement for IRES activity in the context of the
full-length viral mRNA during the viral replication cycle
still remains highly controversial (13). In eukaryotic
mRNAs, the translation initiation complex is recruited
to the vicinity of the 50-cap structure [reviewed in (10)].
However, IRES-mediated translation initiation of viral
mRNAs has emerged as a unique mechanism for
bypassing the requirement of the 50-cap structure
(10,63,64). This strategy would enable viral mRNAs to
overcome cellular translational control normally exerted
at the stage of translation initiation, conferring virus
mRNA a translational advantage over cellular mRNAs
during viral infection, under stress conditions, or during
very speciﬁc phases of the cell cycle (10,63,64). An alter-
native mechanism of translation initiation would thus
ensure that viral protein synthesis is maintained in an eﬃ-
cient and, in some instances, a cell type-speciﬁc manner
when global cap-dependent translation initiation is
repressed (10,64). For instance, the requirement for
an IRES element can potentially be rationalized in
the case of HIV-1 given the constraint to translate its
full-length mRNA during the G2/M phase of the cell
cycle (19,65), where cap-dependent translation initiation
is suppressed (66). A model biological requirement for
IRES function in other retroviruses has yet to be
established.
In this study, we show that the 50-UTR of the full-length
MMTV mRNA harbors an IRES. Translational activity
of the MMTV-IRES was demonstrated in three diﬀerent
experimental systems; RRL, X. laevis oocytes and in cells
(Figures 2–4). We show that translation from the MMTV
50-UTR continues even when eIF4F function is disrupted
(Figure 2B and C). Furthermore, we rule out that the
expression of the second cistron in our bicistronic con-
struct is exclusively due to alternative splicing or cryptic
promoter activity (Figures 3–5). Interestingly, our data
suggest that translation driven from the MMTV IRES
does not require additional viral proteins (Figure 3) and
is not modulated by, at least, the MMTV RemSP protein
(Figure 6). Strikingly, the data do indicate that optimal
MMTV IRES activity requires as yet unidentiﬁed cell-
speciﬁc ITAFs as IRES activity strongly diﬀers in diﬀerent
cellular backgrounds (Figure 4). Alternatively, data may
indicate dissimilar degrees of MMTV IRES-speciﬁc sup-
pression in diﬀerent cell types, i.e. in cell exhibiting rela-
tively high-IRES activity an inhibitory factor(s) might be
lacking.
As for most retroviral IRES elements, the biological
signiﬁcance of the MMTV IRES within the viral context
remains obscure. Yet, it is tempting to speculate that the
presence of an IRES within the 50-UTR of the MMTV
full-length mRNA confers this transcript with a clear
recruitment advantage over cellular mRNAs during
tumorigenesis. Both molecular and epidemiological data
have indicated a possible role for the MMTV, associated
with breast cancer and T-cell lymphomas in mice,
in a certain percentage of human breast tumors (67).
This notion has been recently strengthened by data
demonstrating that MMTV infects and rapidly propagates
in cultured human breast cells (3,4). Yet, there is no deﬁn-
itive evidence to date as to whether MMTV is causal or
merely an innocuous infection in humans.
Translation regulation plays a key role in cancer devel-
opment and progression, impacting on tumor cell prolif-
eration and growth, response to stresses such as hypoxia
and stimulation by mitogenic signals and cell hormone
receptors (68). The presence of IRES elements in so
many genes that are involved in cell growth, proliferation,
apoptosis and angiogenesis raises the possibility that
deregulated internal (cap independent) initiation may
contribute toward tumorigenesis (http://iresite.org/ or
http:www.rangueil.inserm.fr/iresdatabase/). In keeping
with this notion, aberrant translational regulation of the
c-myc IRES has been associated with human neoplasia
multiple myeloma (69–71). In this context, a recent
report established that a switch from cap-dependent to
cap-independent mRNA translation, mediated by
hypoxia, in large advanced breast cancers is required for
promoting angiogenesis, tumor survival and progres-
sion (72). The translational switch is the result of
over-expression of 4E-BP1, the eIF4E-binding protein,
resulting in the inhibition of cap-dependent translation
(72). Concomitant with the reduction in cap-mediated
translation initiation, over-expression of 4E-BP1
enhances IRES-dependent translation from mRNAs
encoding HIF1a, VEGF and Bcl2, proteins required for
growth under hypoxic conditions (72). It thus seems plau-
sible to propose that under hypoxic conditions present in
mammary tumors, MMTV IRES-mediated protein syn-
thesis allows eﬃcient virus gene expression, thus increased
virus production during hypoxia. If so, our data would
provide the mechanism by which MMTV proteins are
produced during breast tumor development.
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